Mediford Corporation

Empowering people to create
a brighter and more hopeful life

To create a world where people have the power to choose
their path to mental and physical health and fulfillment.

One-stop services at every stage of Drug Development

About usFrom drug discovery research through post-marketing surveillance, covering both non-clinical and clinical phases

Mediford Corporation originates from two businesses.
One is LSIM Safety Institute Corporation. As a GLP (Good Laboratory Practice) compliant testing institute, this business provides non-clinical testing services such as safety and efficacy evaluation of pharmaceuticals, and regenerative medicine products.
The other is the drug development support business of LSI Medience Corporation. This business offers Bioanalysis Servicess that utilize our advanced analytical technologies including Biomarker Analysis and drug concentration measurement, along with Central Laboratory Services that cover the entire process involved in testing for clinical trials.

By integrating the knowledge and technologies accumulated in both businesses, mediford responds to the diversifying needs of new treatment modalities. In addition, by handling evaluation services through our technical platform that covers both non-clinical and clinical study phases within one company, we make fit-for-purpose proposals with analytical technologies that cover both of these phases.

Looking ahead to the globalization of new drug development, mediford will continue to strive to enhance services including the introduction of new technologies, and strengthen services for global pharmaceutical companies and analytical laboratories. We will also expand partnerships with pharmaceutical companies, ventures, and academia in cutting-edge scientific fields, contributing to the advancement of new drugs and therapies.

Brand Story

Testing & ServiceComprehensive services for drug development

We make fit-for-purpose proposals with our proven analytical technologies,
tailored to the diversifying treatment modalities.

Nonclinical Contract
Research

We contribute to the health of society through our reliable quality and advanced testing technologies.

Bioanalysis Services

We can help accelerate research and development with our highly reliable analytical services.

Central Laboratory
Services

Centralized testing with unified platform and reference ranges for efficient data analysis

Services by Field

We respond to requests in a variety of fields, including pharmaceuticals, regenerative medicine, agricultural chemicals, chemical substances, and cosmetics.

Analytical Instruments

Our laboratories are equipped with advanced instruments that support a wide range of analytical and testing applications.

ALL VIEW

Testing & ServiceAdvanced Solutions

Inhalation Toxicity Study

Our inhalation toxicity studies draw on nearly 40 years of experience and commitment to global standards.
Mediford provides highly reliable data through assured quality at GLP-compliant and fully AAALAC-accredited facilities, utilizing optimal study designs based on extensive experience.

Best Practice hERG Assay

hERG channel plays an important role in cardiac safety assessment. Mediford performs Best Practice hERG assay in compliance with GLP (Good Laboratory Practice) according to the new ICH S7B Guideline Q&As. Our staff's proficiency with the patch-clamp method provides our clients with high-quality data quickly and efficiently.

Microsampling

Mediford Corporation has introduced microsampling for non-clinical toxicity studies taking into consideration the 3Rs of animal testing. Microsampling is a technique in which a small amount of blood is collected to measure drug concentrations. By using this technique, fewer animals are used than with conventional methods, and the amount of test substance required can be reduced, which is expected to result in total costs being lower.

Patient-Derived Xenografts (PDX) for Drug Development

Mediford Corporation offers a variety of contract services from establishment and banking of PDX-derived cell lines to conducting pharmacological studies at the GLP-certified facilities of Kumamoto Laboratories. The PDX models are more predictive of clinical outcomes than conventional "cancer cell lines" and will be useful for your research and development purposes.

Drug Discovery Support Services Using PDC

Patient-Derived Cells (PDC) for Drug Development

Mediford Corporation provides various contract services using clinical isolates (PDC: Patient-Derived Cell) established at the National Cancer Center in Japan.

Contract Services for Regenerative Medicine Products

Regenerative Medicine Products Development Support

We provide a wide range of services in the development of regenerative medicine products from consulting to medical writing for diseases that are difficult to treat with conventional methods. We support each stage of the development process up to submission of application for approval by providing contract services that meet a wide variety of research needs, including toxicity studies (GLP), efficacy and biodistribution studies (reliability standards), and medical writing at research facilities fully accredited by AAALAC.

Mass Spectrometry Imaging

Mass spectrometry imaging (MSI), is a molecular imaging technique that visualizes the distribution of compounds present on tissue sections by ionizing and measuring them with a mass spectrometer. Mediford Corporation conducts various analyses using cutting-edge MSI equipment.

PBMC Isolation and Analysis

For many years, we have been entrusted with PBMC isolations in clinical trials. We pick up blood samples from study sites, and highly skilled researchers conduct the PBMC isolation process at our GLP laboratory located in Itabashi, Tokyo.

Nucleic Acid Drug Analysis

Mediford Corporation conducts the development and validation of analytical methods, as well as the determination of drug concentrations for nucleic acid drugs in biological samples such as plasma and tissue under the framework of GLP (Good Laboratory Practice). We also carry out metabolite screening studies for nucleic acid drugs in accordance with reliability standards.

Analytical Solutions for Novel Modalities

In recent years, drug development has expanded beyond small molecule drugs to include a range of molecule sizes ―from medium-sized to large molecules― such as nucleic acid drugs, antibody drugs and gene therapy products, utilizing a variety of drug discovery technologies.
Mediford Corporation leverages decades of expertise in small molecule drugs, combined with cutting-edge equipment, to provide reliable data across various modalities.